NCT01737905View on ClinicalTrials.gov

Evaluation of Efficacy and Safety for Single Dose of E004 in Children With Asthma

PHASE3CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

October 31, 2012

Primary Completion Date

March 31, 2013

Study Completion Date

December 31, 2013

Conditions
Asthma
Interventions
DRUG

Epinephrine HFA-MDI (E004)

Single dose 125 mcg/inhalation, 2 inhalations

DRUG

Placebo-HFA

Single dose 0 mcg/inhalation, 2 inhalations

Trial Locations (6)

78229

Sylvana Research Assocaites, San Antonio

79903

Western Sky Medical, El Paso

90630

West Coast Clinical Trials Global, Cypress

97202

Transitional Clinical Research, Inc. Allergy Associates Research Center, Portland

97504

The Clinical Research Institute of Southern Oregn, PC, Medford

98115

ASTHMA, Inc. Clinical Research Center, Seattle

Sponsors
All Listed Sponsors
lead

Amphastar Pharmaceuticals, Inc.

INDUSTRY